Abstract
Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly discovered therapeutic targets. Technical advances in analytical techniques mean that the use of natural products is easier than before. However, there is a widening gap between natural-product researchers in countries rich in biodiversity and drug discovery scientists immersed in proteomics and high-throughput screening.
Original language | English |
---|---|
Pages (from-to) | 196-198 |
Number of pages | 3 |
Journal | Trends in Pharmacological Sciences |
Volume | 20 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 May 1999 |
Keywords
- biological products
- pharmaceutical chemistry
- molecular cloning
- preclinical drug evaluation
- ecosystem
- humans